121 related articles for article (PubMed ID: 38036042)
21. MiR-488 inhibits proliferation and cisplatin sensibility in non-small-cell lung cancer (NSCLC) cells by activating the eIF3a-mediated NER signaling pathway.
Fang C; Chen YX; Wu NY; Yin JY; Li XP; Huang HS; Zhang W; Zhou HH; Liu ZQ
Sci Rep; 2017 Jan; 7():40384. PubMed ID: 28074905
[TBL] [Abstract][Full Text] [Related]
22. Androgen receptor suppresses lung cancer invasion and increases cisplatin response
Liu S; Hu C; Li M; Zhou W; Wang R; Xiao Y
Int J Biol Sci; 2023; 19(12):3709-3725. PubMed ID: 37564195
[TBL] [Abstract][Full Text] [Related]
23. Effect of vitamin D on malignant behavior of non-small cell lung cancer cells.
Songyang Y; Song T; Shi Z; Li W; Yang S; Li D
Gene; 2021 Feb; 768():145309. PubMed ID: 33197518
[TBL] [Abstract][Full Text] [Related]
24. TRIM17-mediated ubiquitination and degradation of RBM38 promotes cisplatin resistance in non-small cell lung cancer.
Zhong T; Zhang J; Liu X; Li H
Cell Oncol (Dordr); 2023 Oct; 46(5):1493-1507. PubMed ID: 37219768
[TBL] [Abstract][Full Text] [Related]
25. circ_0007385 served as competing endogenous RNA for miR-519d-3p to suppress malignant behaviors and cisplatin resistance of non-small cell lung cancer cells.
Ye Y; Zhao L; Li Q; Xi C; Li Y; Li Z
Thorac Cancer; 2020 Aug; 11(8):2196-2208. PubMed ID: 32602212
[TBL] [Abstract][Full Text] [Related]
26. Gefitinib sensitization of cisplatin-resistant wild-type EGFR non-small cell lung cancer cells.
Li A; Cao W; Liu X; Zhang Y; Ma Y; Xu R; Zhang R; Liu X; Zhou S; Wang R; Liu J; Tang X
J Cancer Res Clin Oncol; 2020 Jul; 146(7):1737-1749. PubMed ID: 32342201
[TBL] [Abstract][Full Text] [Related]
27. Targeting NF-κB-mediated inflammatory pathways in cisplatin-resistant NSCLC.
Ryan SL; Beard S; Barr MP; Umezawa K; Heavey S; Godwin P; Gray SG; Cormican D; Finn SP; Gately KA; Davies AM; Thompson EW; Richard DJ; O'Byrne KJ; Adams MN; Baird AM
Lung Cancer; 2019 Sep; 135():217-227. PubMed ID: 31446998
[TBL] [Abstract][Full Text] [Related]
28. Circular RNA hsa_circ_0068252 Functions in Cisplatin Resistance and Immune Response via miR-1304-5p/PD-L1 Axis in Non-Small Cell Lung Cancer.
Li J; Xu J; Wu G; Ren Y; Wang X; Zhang Q
Chemotherapy; 2022; 67(4):223-233. PubMed ID: 35649347
[TBL] [Abstract][Full Text] [Related]
29. LncRNA SNHG12 in extracellular vesicles derived from carcinoma-associated fibroblasts promotes cisplatin resistance in non-small cell lung cancer cells.
Tan D; Li G; Zhang P; Peng C; He B
Bioengineered; 2022 Jan; 13(1):1838-1857. PubMed ID: 35014944
[TBL] [Abstract][Full Text] [Related]
30. SIRT1 and AMPK mediate hypoxia-induced resistance of non-small cell lung cancers to cisplatin and doxorubicin.
Shin DH; Choi YJ; Park JW
Cancer Res; 2014 Jan; 74(1):298-308. PubMed ID: 24240701
[TBL] [Abstract][Full Text] [Related]
31. Meta-analysis of microarray data to determine gene indicators involved in cisplatin resistance in non-small cell lung cancer.
Sheikhshabani SH; Modarres P; Ghafouri-Fard S; Amini-Farsani Z; Khodaee L; Shaygan N; Amini-Farsani Z; Omrani MD
Cancer Rep (Hoboken); 2024 Feb; 7(2):e1970. PubMed ID: 38351531
[TBL] [Abstract][Full Text] [Related]
32. Characterization of the nucleotide excision repair pathway and evaluation of compounds for overcoming the cisplatin resistance of non‑small cell lung cancer cell lines.
Suzuki T; Sirimangkalakitti N; Baba A; Toyoshima-Nagasaki R; Enomoto Y; Saito N; Ogasawara Y
Oncol Rep; 2022 Apr; 47(4):. PubMed ID: 35147203
[TBL] [Abstract][Full Text] [Related]
33. FIGNL1 is a potential biomarker of cisplatin resistance in non-small cell lung cancer.
Meng C; Yang Y; Ren P; Ju Q; Jin X; Long Q; Chen X; Wang X; Li F
Int J Biol Markers; 2022 Sep; 37(3):260-269. PubMed ID: 35791674
[TBL] [Abstract][Full Text] [Related]
34. Circ_0000079 Decoys the RNA-Binding Protein FXR1 to Interrupt Formation of the FXR1/PRCKI Complex and Decline Their Mediated Cell Invasion and Drug Resistance in NSCLC.
Chen C; Zhang M; Zhang Y
Cell Transplant; 2020; 29():963689720961070. PubMed ID: 32951448
[TBL] [Abstract][Full Text] [Related]
35. Cisplatin-induced apoptosis in non-small-cell lung cancer cells is dependent on Bax- and Bak-induction pathway and synergistically activated by BH3-mimetic ABT-263 in p53 wild-type and mutant cells.
Matsumoto M; Nakajima W; Seike M; Gemma A; Tanaka N
Biochem Biophys Res Commun; 2016 Apr; 473(2):490-6. PubMed ID: 26996126
[TBL] [Abstract][Full Text] [Related]
36. LncRNA NNT-AS1 is a major mediator of cisplatin chemoresistance in non-small cell lung cancer through MAPK/Slug pathway.
Cai Y; Dong ZY; Wang JY
Eur Rev Med Pharmacol Sci; 2018 Aug; 22(15):4879-4887. PubMed ID: 30070323
[TBL] [Abstract][Full Text] [Related]
37. SNHG14 silencing suppresses the progression and promotes cisplatin sensitivity in non-small cell lung cancer.
Jiao P; Hou J; Yao M; Wu J; Ren G
Biomed Pharmacother; 2019 Sep; 117():109164. PubMed ID: 31252267
[TBL] [Abstract][Full Text] [Related]
38. ELF1 activated long non-coding RNA CASC2 inhibits cisplatin resistance of non-small cell lung cancer via the miR-18a/IRF-2 signaling pathway.
Xiao XH; He SY
Eur Rev Med Pharmacol Sci; 2020 Mar; 24(6):3130-3142. PubMed ID: 32271431
[TBL] [Abstract][Full Text] [Related]
39. LncRNA TATDN1 contributes to the cisplatin resistance of non-small cell lung cancer through TATDN1/miR-451/TRIM66 axis.
Wang L; Shang X; Feng Q
Cancer Biol Ther; 2019; 20(3):261-271. PubMed ID: 30481109
[TBL] [Abstract][Full Text] [Related]
40. Cisplatin-enriching cancer stem cells confer multidrug resistance in non-small cell lung cancer via enhancing TRIB1/HDAC activity.
Wang L; Liu X; Ren Y; Zhang J; Chen J; Zhou W; Guo W; Wang X; Chen H; Li M; Yuan X; Zhang X; Yang J; Wu C
Cell Death Dis; 2017 Apr; 8(4):e2746. PubMed ID: 28406482
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
